目的 系統(tǒng)評(píng)價(jià)卡貝縮宮素對(duì)比縮宮素預(yù)防產(chǎn)后出血的臨床療效和安全性。方法 計(jì)算機(jī)檢索EMbase、PubMed、中國期刊全文數(shù)據(jù)庫（CNKI）、維普中文科技期刊全文數(shù)據(jù)庫（VIP）、中國生物醫(yī)學(xué)文獻(xiàn)數(shù)據(jù)庫（CBM）和萬方數(shù)據(jù)庫，收集卡貝縮宮素對(duì)比縮宮素用于預(yù)防產(chǎn)后出血的隨機(jī)對(duì)照研究（RCT），檢索時(shí)限均從2000年1月至2017年12月。由2位研究者篩選文獻(xiàn)、提取資料，采用Rev Man 5.1軟件進(jìn)行Meta-分析。結(jié)果 共納入14個(gè)RCTs，3 052例患者。Meta-分析結(jié)果顯示相對(duì)于縮宮素，卡貝縮宮素能顯著降低產(chǎn)后出血率[OR=0.48，95% CI（0.36~0.63），P<0.001]，術(shù)中出血量[MD=-67.31，95% CI（-86.34~-48.28），P<0.001]、術(shù)后2 h出血量[MD=-50.43，95% CI（-71.32~-29.55），P<0.001]和術(shù)后24 h出血量[MD=-62.87，95% CI（-85.59~-40.16），P<0.001]；血紅蛋白減少[MD=-4.24，95% CI（-6.16~-2.31），P<0.001]和不良反應(yīng)發(fā)生率[OR=0.52，95% CI（0.41~0.65），P<0.001]。結(jié)論 本研究結(jié)果顯示卡貝縮宮素預(yù)防產(chǎn)后出血的臨床療效和安全性優(yōu)于縮宮素，值得臨床推廣。

Objective To evaluate the effectiveness and safety of caebetocin vs oxytocin in prevention of postpartum hemorrhage of cesarean section. Methods The related literatures were searched in the following databases:PubMed, EMbase, CNKI, VIP, and WanFang Data from January 2000 to December 2017. Randomized controlled trial (RCT) of caebetocin vs oxytocin in prevention of postpartum hemorrhage of cesarean section was included. Two reviewers independently screened literatures and extracted data. Meta-analysis was conducted by RevMan 5.1 software. Results A total of 14 RCTs were collected, including 3 052 patients. The Meta-analysis showed that:compared with oxytocin, caebetocin could significantly reduce the rate of postpartum hemorrhage[OR=0.48, 95% CI(0.36~0.63), P<0.001]; intraoperative bleeding[MD=-67.31, 95% CI(-86.34~-48.28), P<0.001], postoperative 2 h bleeding[MD=-50.43, 95% CI(-71.32~-29.55), P<0.001], and postoperative 24 h bleeding[MD=-62.87, 95% CI(-85.59~-40.16), P<0.001]; hemoglobin reduction[MD=-4.24, 95% CI(-6.16~-2.31), P<0.001] and incidence of adverse reactions[OR=0.52,95% CI(0.41~0.65), P<0.001]. Conclusion The results of this study showed that the clinical efficacy and safety of caebetocin is better than oxytocin in prevention of postpartum hemorrhage, and it is worthy of clinical use.